Reviva Pharmaceuticals I... (RVPH)
NASDAQ: RVPH
· Real-Time Price · USD
0.35
-0.41 (-54.17%)
At close: Jun 26, 2025, 3:59 PM
Reviva Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -6.28M | -8.46M | -8.13M | -7.92M | -9.99M | -10.71M | -12.07M | -6.74M | -7.77M | -3.56M | -5.52M | -7.45M | -3.96M | -2.48M | -1.79M | -1.87M |
Interest Income | 47.41K | 53.25K | 87.61K | 173.1K | 157.11K | 91.76K | 103.08K | 147.01K | 125.84K | 49.51K | 7.68K | n/a | n/a | n/a | n/a | 148.00 |
Pretax Income | -6.25M | -8.37M | -7.85M | -7.43M | -9.73M | -10.48M | -12.44M | -6.6M | -8.11M | -3.51M | -5.33M | -7.36M | -3.68M | -2.28M | -1.6M | -948.5K |
Net Income | -6.26M | -8.37M | -7.86M | -7.43M | -9.72M | -10.49M | -12.44M | -6.6M | -8.12M | -3.52M | -5.34M | -7.37M | -3.68M | -2.28M | -1.61M | -949.3K |
Selling & General & Admin | 1.6M | 1.6M | 2.55M | 2.14M | 1.51M | 1.99M | 3.08M | 1.5M | 1.48M | 1.26M | 1.01M | 1.62M | 1.3M | 1.05M | 1.42M | 1.48M |
Research & Development | 4.68M | 6.86M | 5.58M | 5.78M | 8.48M | 8.72M | 8.99M | 5.24M | 6.3M | 2.31M | 4.51M | 5.83M | 2.66M | 1.42M | 374.33K | 391.16K |
Other Expenses | n/a | n/a | n/a | n/a | n/a | 5.19K | -19 | -14.49K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 6.28M | 8.46M | 8.13M | 7.92M | 9.99M | 10.71M | 12.07M | 6.74M | 7.77M | 3.56M | 5.52M | 7.45M | 3.96M | 2.48M | 1.79M | 1.87M |
Interest Expense | 4.71K | 5.15K | 5.15K | 3.49K | -20.41K | 5.9K | 12.76K | 7.66K | 133.29K | 49.51K | 7.68K | 232.00 | n/a | 547.00 | 3.55K | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 6.28M | 8.46M | 8.13M | 7.92M | 9.99M | 10.71M | 12.07M | 6.74M | 7.77M | 3.56M | 5.52M | 7.45M | 3.96M | 2.48M | 1.79M | 1.87M |
Income Tax Expense | 4.73K | n/a | 7.38K | 7.4K | -4.58K | 12.12K | 6.44K | 2.98K | 8.36K | 1.86K | 6.92K | 3.63K | -274.27K | 2.1K | 3.9K | 800.00 |
Shares Outstanding (Basic) | 33.15M | 33.8M | 30.56M | 29.89M | 27.56M | 24.03M | 22.43M | 21.83M | 20.45M | 19.27M | 18.47M | 18.47M | 14.43M | 18.46M | 12.87M | 9.23M |
Shares Outstanding (Diluted) | 33.15M | 33.8M | 30.56M | 29.89M | 27.56M | 24.03M | 22.43M | 21.83M | 20.45M | 19.27M | 18.47M | 18.47M | 14.43M | 18.46M | 12.87M | 9.23M |
EPS (Basic) | -0.15 | -0.25 | -0.26 | -0.25 | -0.35 | -0.44 | -0.55 | -0.3 | -0.4 | -0.18 | -0.29 | -0.4 | -0.26 | -0.12 | -0.12 | -0.1 |
EPS (Diluted) | -0.15 | -0.25 | -0.26 | -0.25 | -0.35 | -0.44 | -0.55 | -0.3 | -0.4 | -0.18 | -0.29 | -0.4 | -0.26 | -0.12 | -0.12 | -0.1 |
EBITDA | -6.25M | n/a | -7.85M | -7.42M | -9.39M | -10.61M | -11.97M | -6.6M | -7.31M | -3.56M | -5.7M | -7.54M | -3.96M | -2.48M | -1.79M | -1.87M |
EBIT | -6.25M | -8.36M | -7.85M | -7.42M | -10.01M | -10.71M | -12.07M | -6.74M | -7.77M | -3.56M | -5.52M | -7.45M | n/a | n/a | n/a | -1.87M |
Depreciation & Amortization | n/a | n/a | 282.26K | 499.38K | 601.36K | 96.96K | 103.06K | 132.52K | 461.74K | 27.08K | -178.02K | -89.01K | 274.27K | 54K | 55.81K | 148.00 |